Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:23:29.865Z.
Calculation as of: 2026-10-06T19:23:29.865Z.
Quote observation: 2026-10-06T19:20:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 09a0ab09da9db255713b3d52bc1d4f6ff3c974c87d2899d50b33d975ee1631b8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Prelude Therapeutics Incorporated
Market Cap
$214.56M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$212.25M
EBITDA Yield
7.06%
TTM Avg
4.54%
3Y Avg
3.13%
5Y Avg
3.13%
Market Cap
$211.00M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$210.02M
EBITDA Yield
N/A
TTM Avg
11.62%
3Y Avg
10.33%
5Y Avg
10.33%
Market Cap
$218.99M
EBITDA Yield
N/A
TTM Avg
143.11%
3Y Avg
143.11%
5Y Avg
143.11%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $214.56M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $211.72M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $212.25M | 7.06% | 4.54% | 3.13% | 3.13% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $211.00M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $210.68M | N/A | 17.11% | 12.89% | 12.89% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.02M | N/A | 11.62% | 10.33% | 10.33% |
| Keros Therapeutics, Inc. (KROS)vs › | $218.99M | N/A | 143.11% | 143.11% | 143.11% |
| Pro-Dex, Inc. (PDEX)vs › | $207.78M | 6.61% | 7.98% | 8.26% | 7.82% |
| Profound Medical Corp. (PROF)vs › | $220.57M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $206.50M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
